The first oral session in the acute myeloid leukemia (AML) translational research track of June 15, was given by Eliza Yankova, from the University of Cambridge, who presented collaborative studies done together with Storm Therapeutics Ltd. outlining pharmacological inhibition of METTL1 as a therapeutic strategy in AML treatment.
Samsara Therapeutics Inc. has described autophagy inducers reported to be useful for the treatment of amyotrophic lateral sclerosis and Parkinson’s disease.
Alterome Therapeutics Inc. has disclosed RAC-α serine/threonine-protein kinase (AKT1; PKBα) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.
Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.
Rgenta Therapeutics Inc. has presented their work on the discovery and development of RGT-61159, a potential first-in-class oral inhibitor of the oncogenic transcription factor c-MYB.
Opus Genetics Inc. has received $1.7 million in project-based funding from the Foundation Fighting Blindness to help advance two preclinical candidate programs for inherited retinal diseases.
Investigators from CMR Curediab Metabolic Research GmbH recently disclosed preclinical data for a novel hepatoprotective thioacrylamide compound, HK-3, being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Santa Ana Bio Inc. has emerged from stealth with $168 million in combined series A and B funding and a focus on developing targeted therapies for patients with autoimmune and inflammatory diseases.
RSS
